Breaking News Instant updates and real-time market news.

PTLA

Portola Pharmaceuticals

$30.74

-7.03 (-18.61%)

05:49
08/10/18
08/10
05:49
08/10/18
05:49

Portola Pharmaceuticals downgraded to Underperform at Credit Suisse

  • 25

    Aug

PTLA Portola Pharmaceuticals
$30.74

-7.03 (-18.61%)

05/07/18
SBSH
05/07/18
NO CHANGE
Target $64
SBSH
Buy
Portola Pharmaceuticals price target raised to $64 from $58 at Citi
Citi analyst Yigal Nochomovitz raised his price target for Portola Pharmaceuticals to $64 following the FDA approval of Andexxa. The analyst keeps a Buy rating on the shares.
05/07/18
OPCO
05/07/18
NO CHANGE
Target $80
OPCO
Outperform
Portola Pharmaceuticals price target raised to $80 from $67 at Oppenheimer
Oppenheimer analyst Jay Olson raised his price target for Portola Pharmaceuticals to $80 from $67 after AndexXa received FDA approval as the first and only antidote indicated for patients treated with rivaroxaban and apixaban when reversal is needed in the case of life-threatening or uncontrolled bleeding. The analyst believes potential drivers of upside include AndexXa likely expanding factor Xa use and label extensions, U.S. approval of Gen2 manufacturing to expand capacity, European CHMP opinion in Q4 and cerdulatinib data at ASCO. Olson reiterates an Outperform rating on the shares.
05/07/18
MSCO
05/07/18
NO CHANGE
Target $46
MSCO
Equal Weight
Portola price target raised to $46 from $31 at Morgan Stanley
Morgan Stanley analyst Matthew Harrison raised his price target on Portola Pharmaceuticals to $46 following the FDA approval of AndexXa, calling it a significant positive. However, he maintains an Equal Weight rating on the shares, as he expects the stock to trade with the market given the limited launch will not allow investors to gauge true demand until 2019.
06/14/18
SBSH
06/14/18
NO CHANGE
SBSH
Buy
Portola not planning sale despite CEO transition, says Citi
Citi analyst Yigal Nochomovitz asked Portola Pharmaceuticals if the CEO transition means the company is potentially up for sale. Management emphasized that the CEO transition should not be interpreted as meaning they are planning to sell the company, Nochomovitz tells investors in a research note. He points out that management reiterated they are working towards advancing the company commercially. With two approved drugs in thrombosis, Portola views itself as well positioned to attract new talent to continue to build its sales force, Nochomovitz writes after speaking to the company. He keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

EADSY

Airbus

$0.00

(0.00%)

06:14
01/24/19
01/24
06:14
01/24/19
06:14
Periodicals
Airbus CEO issues warning about jobs in event of no-deal Brexit, Reuters reports »

Airbus CEO Tom Enders…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBGI

Sinclair Broadcast

$30.55

1 (3.38%)

06:11
01/24/19
01/24
06:11
01/24/19
06:11
Periodicals
Sinclair Broadcast hires liberal commentator Ameshia Cross, WSJ reports »

Sinclair Broadcast, known…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROST

Ross Stores

$91.51

-0.13 (-0.14%)

06:10
01/24/19
01/24
06:10
01/24/19
06:10
Recommendations
Ross Stores analyst commentary  »

Ross Stores price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTL

CenturyLink

$15.22

-0.18 (-1.17%)

06:08
01/24/19
01/24
06:08
01/24/19
06:08
Downgrade
CenturyLink rating change  »

CenturyLink downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

  • 25

    Feb

ASND

Ascendis Pharma

$73.16

-0.47 (-0.64%)

06:07
01/24/19
01/24
06:07
01/24/19
06:07
Upgrade
Ascendis Pharma rating change  »

Ascendis Pharma upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FFIV

F5 Networks

06:07
01/24/19
01/24
06:07
01/24/19
06:07
Recommendations
F5 Networks analyst commentary  »

F5 Networks price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLTH

Duluth Holdings

$20.41

0.425 (2.13%)

06:07
01/24/19
01/24
06:07
01/24/19
06:07
Upgrade
Duluth Holdings rating change  »

Duluth Holdings upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSANY

Nissan

$0.00

(0.00%)

, RNSDF

Renault

$0.00

(0.00%)

06:06
01/24/19
01/24
06:06
01/24/19
06:06
Hot Stocks
Nissan plans April investor meeting to oust Ghosn from board »

Nissan (NSANY) announced…

NSANY

Nissan

$0.00

(0.00%)

RNSDF

Renault

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGI

Triumph Group

$13.27

-0.07 (-0.52%)

, BDRBF

Bombardier

$0.00

(0.00%)

06:05
01/24/19
01/24
06:05
01/24/19
06:05
Hot Stocks
Bombardier to acquire Global 7500 aircraft wing program from Triumph Group »

Bombardier (BDRBF)…

TGI

Triumph Group

$13.27

-0.07 (-0.52%)

BDRBF

Bombardier

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

RNSDF

Renault

$0.00

(0.00%)

06:05
01/24/19
01/24
06:05
01/24/19
06:05
Periodicals
Renault's board asked to name Senard, Bollare to replace Ghosn, Reuters says »

Renault's board will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$9.04

0.195 (2.20%)

06:03
01/24/19
01/24
06:03
01/24/19
06:03
Periodicals
Deutsche Bank gets inquiry from House panels on Trump ties, Reuters reports »

Deutsche Bank has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POST

Post Holdings

$99.46

-1.16 (-1.15%)

06:03
01/24/19
01/24
06:03
01/24/19
06:03
Downgrade
Post Holdings rating change  »

Post Holdings downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 01

    Feb

MTL

Mechel

$2.50

0.075 (3.10%)

06:01
01/24/19
01/24
06:01
01/24/19
06:01
Hot Stocks
Mechel launches steel trade online store »

Mechel reports launching…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RNSDF

Renault

$0.00

(0.00%)

, NSANY

Nissan

$0.00

(0.00%)

06:01
01/24/19
01/24
06:01
01/24/19
06:01
Periodicals
Carlos Ghosn resigns as head of Renault, Bloomberg reports »

Carlos Ghosn has resigned…

RNSDF

Renault

$0.00

(0.00%)

NSANY

Nissan

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

URGN

UroGen Pharma

$45.90

-7.6 (-14.21%)

06:00
01/24/19
01/24
06:00
01/24/19
06:00
Syndicate
UroGen Pharma 3.66M share Secondary priced at $41.00 »

Goldman Sachs, JPMorgan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

GRBK

Green Brick

$8.13

0.13 (1.63%)

06:00
01/24/19
01/24
06:00
01/24/19
06:00
Initiation
Green Brick initiated  »

Green Brick initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EHTH

eHealth

$51.39

6.01 (13.24%)

05:59
01/24/19
01/24
05:59
01/24/19
05:59
Syndicate
eHealth 2.4M share Secondary priced at $48.50 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

INCY

Incyte

$75.20

-2.11 (-2.73%)

05:59
01/24/19
01/24
05:59
01/24/19
05:59
Upgrade
Incyte rating change  »

Incyte upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

BID

Sotheby's

$41.07

-0.27 (-0.65%)

05:57
01/24/19
01/24
05:57
01/24/19
05:57
Downgrade
Sotheby's rating change  »

Sotheby's downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$89.55

-0.89 (-0.98%)

05:57
01/24/19
01/24
05:57
01/24/19
05:57
Recommendations
Xilinx analyst commentary  »

Xilinx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

FISV

Fiserv

$80.62

2.32 (2.96%)

05:57
01/24/19
01/24
05:57
01/24/19
05:57
Upgrade
Fiserv rating change  »

Fiserv upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOS

Canada Goose

$49.59

-0.4 (-0.80%)

05:57
01/24/19
01/24
05:57
01/24/19
05:57
Downgrade
Canada Goose rating change  »

Canada Goose downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTRS

Northern Trust

$89.93

-0.67 (-0.74%)

05:56
01/24/19
01/24
05:56
01/24/19
05:56
Downgrade
Northern Trust rating change  »

Northern Trust downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Feb

  • 28

    Feb

UMC

UMC

$1.84

-0.01 (-0.54%)

05:55
01/24/19
01/24
05:55
01/24/19
05:55
Downgrade
UMC rating change  »

UMC downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBF

SoftBank

$0.00

(0.00%)

05:55
01/24/19
01/24
05:55
01/24/19
05:55
Periodicals
SoftBank's Vision Fund to make $100M investment in Globality, WSJ reports »

SoftBank is investing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.